Sign inStart free

Health Care · Pharmaceutical Preparations

TVRD Tvardi Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1346830101 filings
Russell 2000
Follow TVRD for alertsAsk AI about TVRD

TVRD at a glance

Tvardi Therapeutics, Inc. (TVRD, SEC CIK 1346830) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on August 14, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2024 (FY2024), Tvardi Therapeutics, Inc. (TVRD) reported revenue of $7.1 million (down 66.0% from FY2023) and a net loss of $70.9 million. Diluted EPS was -$15.53.
  • As of June 30, 2026, 13 institutional investment managers tracked by SignalX reported holding Tvardi Therapeutics, Inc. (TVRD) shares worth $1.3 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2024
$7.1M
−66.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
13 funds
$1.3M · −3 vs prior quarter
Latest 8-K
Aug 14, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY; no product revenue since inception
  • Net loss $6.5M vs net income $4.2M YoY
  • TTI-109 largest R&D focus; TTI-101 HCC trial also incurred costs
  • Cash and equivalents $15.8M at June 30, 2026; accumulated deficit $123.7M
  • Topline TTI-101 HCC data expected Q4 2026; additional funding required with going-concern doubt

Risk Factors

  • Risk Factors section not provided; no new or changed risks identifiable from supplied text
  • Capital on Demand™ Sales Agreement dated May 1, 2026, indicating potential equity-financing dilution
  • No director or officer Rule 10b5-1 trading arrangements adopted or terminated during the quarter
  • No defaults upon senior securities reported

AI summary of the TVRD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Aug 14, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Item 2.02 references earnings-related disclosure, but the excerpt contains only exhibit liability language
  • Exhibit excluded from Exchange Act Section 18 liability and Securities Act Sections 11 and 12(a)(2) liability

Item EX-99.1: Item EX-99.1

  • TTI-109 healthy-volunteer data confirmed TTI-101-equivalent exposure, improved tolerability, and reductions in UC-relevant immune populations
  • UC selected as lead indication; U.S. addressable market approximately $3B versus $9B globally
Filed Jul 30, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Exhibits 99.1 and 99.2 furnished under Regulation FD
  • Disclosure not deemed filed under Exchange Act Section 18

Item EX-99.1: Item EX-99.1

  • TTI-109 selected for ulcerative colitis after Phase 1 healthy-volunteer study, establishing UC as the company’s lead development focus
  • Immune-cell reductions reached 76% for Th17 subsets, 43% for Tfh subsets and 71% for B-cell subsets linked to UC pathology
Filed Jul 17, 2026Full analysis →

Item 8.01: Other Events

  • ATM offering increased by up to $9.69 million, expanding potential equity financing capacity
  • $11.0 million gross proceeds from 3,110,769 shares sold during prior twelve-month period

AI summaries of TVRD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TVRD

Don't miss the next TVRD filing

  • Alerts as it files. A push when TVRD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TVRD, by share count.
  • Ask anything. An AI agent that reads every TVRD filing and answers with sources.
Follow TVRD for alertsAsk AI about TVRD
Compare plans →

TVRD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
HALL WALLACE L JRAJun 9, 2026-
Shah SujalAJun 9, 2026-
Smith CynthiaAJun 9, 2026-
WYZGA MICHAEL SAJun 9, 2026-
Shiff Susan Ph.D.AJun 9, 2026-
Alibhai Imran NizamudinAJan 29, 2026-
Conn Avi DanielAJan 29, 2026-
Kauh John Saewook M.D.AJan 29, 2026-
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$21.0M$7.1M-
Operating Income-$121.5M-$58.4M-$26.7M
Net Income--$70.9M-$18.2M
Op. Margin-579.4%-818.0%-
Net Margin--993.0%-
Balance Sheet
Total Assets$125.8M$43.8M$32.1M
Equity--$4.6M$20.9M
ROE-1542.9%-87.0%
Per Share
EPS$-2.19$-15.53$-3.26
Cash Flow
Operating CF-$92.1M-$60.9M-$23.5M
CapEx$2.4M$1.0M-

Source: XBRL data in Tvardi Therapeutics, Inc. (TVRD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate TVRD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TVRD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202613$1.3M
Q1 202616$3.7M
Q4 202516$5.6M
Q3 202515$43.2M
Q2 202512$18.6M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 72 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TVRD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KAug 14, 2026Analysis-
10-QAug 14, 2026Analysis
8-KJul 30, 2026Analysis-
8-KJul 17, 2026Analysis-
8-KJul 7, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
8-KJun 11, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
8-KMay 8, 2026Analysis
10-QMay 8, 2026Analysis
10-KMar 31, 2026-
8-KMar 31, 2026--
8-KMar 6, 2026Analysis-
4Feb 2, 2026-
4Feb 2, 2026-
4Feb 2, 2026-
4Feb 2, 2026-
8-KJan 16, 2026-
4Dec 18, 2025-
4Dec 18, 2025-
4Dec 18, 2025-
8-KDec 18, 2025-

Related Health Care companies

All Health Care →

TVRD SEC filings: frequently asked questions

Which institutions hold TVRD stock?

As of June 30, 2026, the largest Tvardi Therapeutics, Inc. (TVRD) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($654,000), BlackRock ($181,000), Renaissance Technologies LLC ($174,000), Morgan Stanley ($147,000), State Street Corp ($64,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TVRD's revenue in fiscal year 2024?

For the fiscal year ended December 31, 2024 (FY2024), Tvardi Therapeutics, Inc. (TVRD) reported revenue of $7.1 million (down 66.0% from FY2023) and a net loss of $70.9 million. Diluted EPS was -$15.53. The figures come from the XBRL data in the 10-K.

What did TVRD report in its latest 8-K?

Tvardi Therapeutics, Inc. (TVRD) filed an 8-K on August 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 references earnings-related disclosure, but the excerpt contains only exhibit liability language.

What are the latest TVRD SEC filings?

Tvardi Therapeutics, Inc. (TVRD) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on August 14, 2026 and a Form 4 insider filing on June 11, 2026.

What is TVRD's SEC CIK number?

Tvardi Therapeutics, Inc. (TVRD)'s SEC Central Index Key (CIK) is 1346830. EDGAR lists every TVRD filing under that number.

Ask anything about TVRD

The research agent reads TVRD's filings, financials, insider trades and 13F holders, then answers with sources.

Start free